Regeneron Ventures

Regeneron Ventures is a corporate venture capital fund established in April 2024, focusing on investing in early-stage biotechnology and health technology companies. Operating independently from its sole limited partner, Regeneron Pharmaceuticals, Inc., the fund shares a patient-centric, science-based mission, principles, and values. Its investment mandate encompasses healthcare broadly, with a particular emphasis on biotechnology, medical devices, tools, and enabling technologies. Investment decisions are based on the quality of the people, science, and data, favoring breakthrough innovations and tolerating risk and uncertainty. The fund aims to help portfolio companies transform great ideas into impactful products for patients, driving investment results through this mission. The general partner is independently managed by former Regeneron executives Jay S. Markowitz, M.D., and Michael Aberman, M.D., who lead the fund's investment strategy. Regeneron Pharmaceuticals, Inc. is the fund's exclusive limited partner, committing $100 million annually for five years. The fund operates from Greenwich, Connecticut, and can be contacted via email at info@regeneronventures.com or by phone at +1 855-734-3648. The official website is https://www.regeneronventures.com/.